This page analyzes the coverage of neurodegenerative disease genes within the druggable genome, identifying which disease-relevant genes have known drug targets and where therapeutic development opportunities exist. Understanding druggable genome coverage helps prioritize research efforts and identify unmet therapeutic needs. [1]
The druggable genome refers to genes encoding proteins that can be modulated by drugs, typically including receptors, enzymes, ion channels, and transporters. Current estimates suggest approximately 4,000-5,000 genes are druggable, though fewer than 1,000 are currently targeted by approved drugs. [2]
--- [3]
G-Protein Coupled Receptors (GPCRs): The largest drug target class, with approximately 800 members. GPCRs modulate neurotransmission and are implicated in neurodegenerative diseases. Example targets include mGluR5 (metabotropic glutamate receptor) for AD and D1/D2 dopamine receptors for PD. [4]
Ion Channels: Voltage-gated and ligand-gated ion channels are validated targets. Examples include calcium channel blockers for stroke prevention and NMDA receptor antagonists for ALS.
Enzymes: Kinases, proteases, and other enzymes offer druggable targets. Examples include BACE1 (beta-secretase) for amyloid-beta production and LRRK2 kinase for PD.
Nuclear Receptors: Ligand-activated transcription factors regulate gene expression. PPAR agonists have been explored for neuroinflammation in AD.
| Category | Genes | Percentage |
|---|---|---|
| All protein-coding genes | ~20,000 | 100% |
| Druggable genes (ChEMBL) | ~4,500 | 22.5% |
| Highly druggable (Phase I+) | ~2,000 | 10% |
| Currently targeted by drugs | ~600 | 3% |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| BACE1 | BACE1 | High | Failed (verubecestat) |
| Gamma-secretase | PSEN1/2 | Medium | Failed (semagacestat) |
| Aβ aggregation | APP | Indirect | None |
| Aβ clearance | APOE | Low | Research phase |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| Tau kinases | GSK3B, CDK5 | High | Research phase |
| Tau acetylation | EP300 | Medium | Research phase |
| Tau aggregation | MAPT | Low | Research phase |
| Tau clearance | Macroautophagy | Medium | Research phase |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| Cholinergic | ACHE, BCHE | High | Approved (donepezil) |
| Glutamatergic | NMDA, AMPA | High | Approved (memantine) |
| Serotonergic | HTR1A, HTR2A | High | Research phase |
| Dopaminergic | DRD1-DRD5 | High | Approved (pramipexole) |
Approximately 35% of AD-relevant genes are in the druggable genome, but coverage varies by pathway. Amyloid and tau targets have lower success rates than neurotransmitter modulation.
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| Alpha-synuclein | SNCA | Low | Immunotherapies in trial |
| GBA enzyme | GBA | Medium | Gene therapy approach |
| LRRK2 kinase | LRRK2 | High | DNL151 in trials |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| D1 receptor | DRD1 | High | Approved (pramipexole) |
| D2 receptor | DRD2 | High | Approved (ropinirole) |
| MAO-B | MAOB | High | Approved (selegiline) |
| COMT | COMT | High | Approved (entacapone) |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| Complex I | Multiple | Low | None |
| PINK1 | PINK1 | Medium | Research phase |
| PARKIN | PRKN | Low | Gene therapy |
PD shows good coverage of symptomatic targets (dopamine pathway) but limited disease-modifying targets.
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| SOD1 | SOD1 | High | Gene therapy (tofersen) |
| C9orf72 | C9orf72 | Low | Multiple approaches |
| FUS | FUS | Low | Research phase |
| TDP-43 | TARDBP | Low | Research phase |
| Target | Gene | Druggability | Development Status |
|---|---|---|---|
| NMDA receptor | GRIN1/2 | High | Approved (riamuzide) |
| Antioxidant | NFE2L2 | Medium | Research phase |
| Anti-apoptotic | BCL2 | Medium | Research phase |
ALS has limited druggable genome coverage for major genetic targets, explaining the lack of effective disease-modifying therapies.